Anti-MDA-5 Ab (CADM-140)
Use
Anti-MDA5 antibodies are found in 7% to 35% of adult dermatomyositis cases. These antibodies are associated with clinical features of absent or mild muscle symptoms, called clinical amyopathic dermatomyositis, and can lead to rapidly progressive interstitial lung disease. Specific mucocutaneous features may include skin ulcerations, papules, oral ulcerations, and arthritis, highlighting their significance in diagnosing these conditions.
Special Instructions
This test is part of the Myomarker 3 Profile and Myomarker 3 Profile Plus. Ensure that specimens are sent refrigerated to maintain integrity.
Limitations
Minimum specimen volume of 0.3 mL does not allow for repeat testing, which may limit the ability to confirm results if initial testing is inconclusive or problematic. Gross hemolysis, lipemia, and icterus, as well as specimens other than serum, can lead to specimen rejection.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Result Turnaround Time
9-14 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.3 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot 1 mL of serum into a plastic vial. Send refrigerated.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus, bacterial contamination, specimens other than serum.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 60 days |